Management and prevention of thrombotic stent occlusion
We read with a great interest, the paper by Wenaweser et al. 1 who report the efficacy and outcome of emergency percutaneous coronary interventions in patients with stent thrombosis.
Recently, we published our data on 1519 consecutive patients who underwent 2020 stent implantations and were discharged on dual anti-platelet therapy. We compared the short-and long-term risks of thrombotic stent occlusion (TSO) and mortality in patients given clopidogrel or ticlopidine. 2, 3 The rates of TSO during the first year of follow-up, in our study, were 1.8, 0.7, and 2.8% in the whole group, the ticlopidine group and the clopidogrel group (P , 0.01). A multivariate model showed that clopidogrel (vs. ticlopidine) treatment was the sole predictor of TSO (OR ¼ 5.4, 95% CI ¼ 1.2-24.1, P ¼ 0.028). Of even greater concern, clopidogrel treatment was associated with an increased risk of 1-year mortality (OR ¼ 1.8, 95% CI ¼ 1.2-2.8). Our data are in agreement with those published by Mueller et al. 4 who reported that the extended follow-up data of their initial randomized trial which compared clopidogrel with ticlopidine after stenting. Similar to our findings, these investigators reported a significantly higher rate of mortality, both overall and cardiovascular, in the clopidogrel arm.
Wenaweser et al.
1 report a prevalence of 1.6% of stent thrombosis, a rate that is similar to ours. Clopidogrel was used in many more of their TSO patients than ticlopidine (86 and 14%, respectively).
While the focus of the study of Wenaweser et al. 1 was on the treatment of TSO, we believe that in light of the previous findings, it would be of great interest to know whether Wenaweser et al. The management and prevention of thrombotic stent occlusion: reply Dual antiplatelet therapy with aspirin and thienopyridines has been shown superior to treatment with oral anticoagulation and aspirin alone in the prevention of major adverse cardiac events following coronary stent implantation. 1 The therapeutic benefit of ticlopidine was somewhat limited by rare but potentially serious adverse effects such as neutropenia and thrombocytopenia. The advent of clopidogrel was associated with a superior haematological safety profile but comparable efficacy in three randomized trials and has largely replaced the use of ticlopidine. [2] [3] [4] Notwithstanding, the comparative studies had some limitations: (1) the trials were underpowered to detect small but potentially important differences in the incidence of stent thrombosis; (2) the studies differed with respect to the loading dose regimen; and (3) the follow-up period was limited to 30 days. In light of these limitations, the report of Dr Wolak and colleagues of a higher incidence of stent thrombosis with clopidogrel (2.8%) than ticlopidine (0.7%) in an all-comer population of 1519 consecutive patients undergoing bare metal stent implantation is of interest. Their observation is echoed by the extended follow-up data of the randomized trial reported by Mueller et al. 5 and our own experience. Thus, we have previously investigated the incidence of stent thrombosis following bare metal stent implantation in 4500 consecutive patients. 6 While the overall rate of stent thrombosis was 0.8%, thrombotic stent occlusion occurred in 1.9% of patients with clopidogrel and in 0.6% of patients with ticlopidine treatment (P , 0.05). The mechanism for the observed difference in efficacy between ticlopidine and clopidogrel remains unclear but has been related to differences in drug-drug interaction as well as dose and length of treatment with the respective thienopyridine. Stent thrombosis has gained even more importance in the era of drug eluting stents and future studies with long-term follow-up will have to determine the optimal antiplatelet therapy. Comment on pregnancy and aortic root growth in the Marfan syndrome Meijboom and coworkers 1 reported on the aortic root growth rate of women with Marfan syndrome during pregnancy. They could not find a significant increase in the aortic root diameter in 31 pregnancies of 23 patients and concluded that 'Pregnancy in women with Marfan syndrome seems to be relatively safe up to an aortic root diameter of 45 mm'.
We believe that it is too early to draw such a conclusion. All statistical tests performed in this study were aimed to find any growth. These tests failed, but a power analysis to determine the case number necessary to find any differences was not performed. The authors even reported on one woman with an aortic dissection during pregnancy and on an increased growth of the aortic root during long-term follow-up in those patients with an aortic root diameter .40 mm at baseline in a subgroup analysis.
We recently lost one of our patients, a 36-year-old woman with aortic coarctation and bicuspid aortic valve. These patients usually have structural abnormalities in the aortic medial wall predisposing to dilatation, aneurysm, and rupture, which are similar but less pronounced than those described in Marfan syndrome. 2, 3 This woman died from aortic rupture at the 36th week of her second pregnancy. Her ascending aorta measured 40-41 mm and did not show any progression of diameter assessed several times by echocardiography as well as by helical CT prior to her second pregnancy. Unfortunately, the patient was not seen in our centre during pregnancy, and no consecutive imaging was performed.
Summarizing, this study did not provide real evidence for the conclusion that 'Pregnancy in women with Marfan syndrome seems to be relatively safe up to an aortic root diameter of 45 mm'. We should recommend to monitor all pregnant women with Marfan syndrome very carefully and closely, as suggested in many previous studies, 4, 5 because aortic dissection does not only depend on aortic diameter progression and may also occur in Marfan patients with a normal aortic diameter.
